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Background/aim: The aim of this study was to examine the theory that oxidative stress might have an important mediating effect on the
deleterious results of vitamin B12 metabolism deficiency seen throughout the body.
Materials and methods: Forty patients with vitamin B12 deficiency and 40 healthy controls were included in the study. Venous blood
samples were collected from all participants to evaluate serum vitamin B12, homocysteine, methylmalonic acid, total antioxidant status
(TAS), and total oxidant status (TOS) levels in the pre- and posttreatment periods.
Results: There were no significant differences in TAS, TOS, or oxidative stress index (OSI) levels between the pretreatment patient
and control groups, and there were no significant differences in TAS or TOS levels between the posttreatment and control groups. In
addition, there were no significant differences between the pre- and posttreatment TAS, TOS, and OSI levels of the patients.
Conclusion: These findings are remarkable in that cyanocobalamin treatment had no direct effect on oxidant and antioxidant status in
patients with vitamin B12 deficiency. The fact that there were no differences in oxidant and antioxidant status between the patients and
the controls might suggest that oxidative stress does not play a role in the systemic negative effects of vitamin B12 deficiency.
Key words: Vitamin B12, homocysteine, oxidative stress, total antioxidant status, total oxidant status

1. Introduction
Vitamin B12 is an essential vitamin that plays a crucial role
in many chemical reactions and affects many mechanisms
in the body. Nucleic acid metabolism, transference of
methyl groups, synthesis and repair of myelin sheaths,
and formation of red blood cells are all functions in
which vitamin B12 plays a role (1–4). Vitamin B12
deficiency can lead to a great deal of dysfunction, mainly
hematological and neuropsychic symptoms. The activity
of the methylmalonyl-coenzyme A mutase enzyme is
interrupted by vitamin B12 deficiency, and, as a result,
serum methylmalonic acid (MMA) levels and urine MMA
excretion increase. Vitamin B12 deficiency also interrupts
methionine synthase activity, resulting in elevated serum
homocysteine levels. Homocysteine and MMA levels
increase progressively through the process of vitamin B12
deficiency. For this reason, even in the early stages, it is
important to measure MMA and homocysteine levels; in
particular, a concurrent increase in both serum MMA and
homocysteine levels is accepted as a laboratory marker of
vitamin B12 deficiency (5).
* Correspondence: tekin-guney@hotmail.com
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In vitamin B12 deficiency, regulation of the citric
acid cycle deteriorates due to increasing MMA levels,
and fatty-acid degradation decreases while fatty-acid
synthesis increases; thus, ATP generation is interrupted,
which means that the number of oxidative reactive species
increases in the mitochondria. On the other hand, the levels
of propionic acid, succinate dehydrogenase, cytochrome
C activity, propionyl-CoA, amino acids, cell metabolism,
protein synthesis, fatty-acid synthesis enzymes (ATP
citrate lyase), homocysteine, and MMA increase in cases of
vitamin B12 deficiency (2). Hence, vitamin B12 deficiency
hypothetically results in an effect that favors oxidant
status in the oxidant/antioxidant ratio. Increased levels of
homocysteine, which has a prooxidant capacity, have been
closely related to oxidative stress (6). It has been claimed
that homocysteine triggers oxidative stress by generating
reactive oxygen species, which affects developing disulfide
bonds (7). In addition, the trans-sulfation of homocysteine
to glutathione, which is a major intracellular antioxidant, is
an important metabolic pathway related to homocysteine.
Thus, a decrease in glutathione levels is closely related to
oxidative stress (8).
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Oxidant status can be defined as the total burden that
results from many reactions at a molecular level and has
a negative effect, whereas the protective response that
develops to correspond to the prooxidant molecules is
called the antioxidant effect. Total oxidant status (TOS) has
been identified as the in vivo marker of a shift developing
in an oxidative/antioxidative ratio in favor of the oxidative
side. Total antioxidant status (TAS), on the other hand,
reflects all total plasma antioxidant substrates. Oxidative
stress index (OSI) is an indicator of the degree of oxidative
stress; it is the percentage of the TOS level/TAS level ratio
(9–11).
Vitamin B12 plays a crucial role in DNA, RNA, and
protein syntheses, acting as a cofactor. In addition to the
direct negative effect of vitamin B12 deficiency on the cell
cycle, the increased homocysteine levels that accompany
vitamin B12 deficiency contribute to the deterioration of
multisystem tissues via various molecular and biochemical
pathways. The aim of this study was to examine the theory
that oxidative stress might have an important mediation
effect on the deleterious results of vitamin B12 metabolism
deficiency seen throughout the body by measuring levels
of vitamin B12, MMA, homocysteine, TAS, and TOS and
determining whether there is any relation among them.
2. Materials and methods
2.1. Patients and controls
Forty patients with vitamin B12 deficiency, aged 19–82
years, and 40 healthy volunteer controls, aged 19–64
years, from the Department of Hematology, Faculty of
Medicine of Yıldırım Beyazıt University were included
in the study. Venous blood samples (10 mL) were
collected from all participants to evaluate serum vitamin
B12, homocysteine, MMA, TAS, and TOS levels. After
providing cyanocobalamin treatment for 1 month, another
round of 10-mL venous samples was obtained to test TAS
and TOS levels. Patients with comorbid systemic disorders
and patients using any drugs were excluded from the
study. The control group consisted of healthy adults who
were age- and sex-matched to the vitamin B12 deficiency
participants. Written informed consent was obtained
from all subjects after they were provided with a complete
description of the study. This study was approved by the
ethics committee of the Faculty of Medicine of Yıldırım
Beyazıt University.
2.2. Blood samples and measurement tools
To avoiding interfering with the study results, the
individuals in the patient and control groups were advised
not to smoke, drink, or eat prior to undergoing the blood
sampling. Venous blood samples were collected from an
antecubital vein after an 8-h overnight fasting period;
10 mL of venous blood was drawn from each patient
into biochemistry tubes. The biochemistry tubes were

centrifuged at 1800 × g for 15 min after an incubation
period of 30 min. The samples were frozen at –80 °C and
stored prior to analysis. TAS and TOS were measured using
a Cobas c501 automated analyzer (Roche, Switzerland)
in the Biochemistry Laboratory of Atatürk Training and
Research Hospital.
2.3. Measurement of serum vitamin B12 levels
Serum vitamin B12 levels were analyzed using the
electrochemiluminescence immunoassay method with a
Cobas e601 immunological test autoanalyzer and Elecsys
vitamin B12 test kits (Roche Diagnostics).
2.4. Measurement of plasma homocysteine levels
Homocysteine levels were measured with an Immulite 2000
autoanalyzer, using the chemiluminescence immunoassay
method.
2.5. Measurement of serum MMA levels
MMA levels were measured using liquid chromatography–
mass spectrometry.
2.6. Measurement of plasma TOS
Plasma TOS levels were measured using Erel’s method
for TOS (10). With this method, oxidants present in the
sample oxidize the ferrous ion-o-dianisidine complex to a
ferric ion. The oxidation reaction is enhanced by glycerol
molecules, which are abundantly present in the reaction
medium. The ferric ion forms a colored complex with
xylenol orange in an acidic medium. The color intensity,
which can be measured spectrophotometrically, is related
to the total amount of oxidant molecules present in the
sample. The assay is calibrated with hydrogen peroxide,
and the results are expressed in terms of micromolar
hydrogen peroxide equivalent per liter (µmol H2O2 eqv./L).
2.7. Measurement of plasma TAS
Plasma TAS levels were measured using the method
described by Erel (9). The principle of the assay is to
incubate ABTS (2,2’-azino-di-[3-ethylbenzthiazoline
sulfonate]) with H2O2 to produce the radical cation
ABTS+, which has a relatively stable blue-green color and is
measured at 600 nm. Antioxidants in the added sera cause
bleaching of this color to a degree that is proportional to
their concentrations. The TAS value is expressed as µmol
Trolox eqv./L.
2.8. Determination of OSI
The ratio of TOS to TAS was accepted as the OSI in this
study. To carry out this calculation, the resulting TAS unit
was changed to μmol/L, and the OSI value was calculated
according to the following formula: OSI (arbitrary unit)
TOS (μmol H2O2 eqv./L) / TAS (µmol Trolox eqv./L) (11).
2.9. Statistical analysis
Data analysis was performed using SPSS 11.5 (SPSS Inc.,
Chicago, IL). The Kolmogorov–Smirnov test was used
to determine whether the distribution of continuous
variables was normal. Data were shown as mean ± SD
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or median (min–max), as applicable. Mean differences
between groups were compared using Student’s t-test, and
the Mann–Whitney U test was used for comparisons of the
median values. The Wilcoxon signed rank test was used
to determine whether the differences (in median values)
between pre- and posttreatment measurements were
statistically significant. Nominal data were analyzed by
Pearson’s chi-square test. Degrees of association between
continuous variables were evaluated by Spearman’s rank
correlation analysis. P < 0.05 was considered statistically
significant.
3. Results
This study included 40 patients and 40 healthy controls.
The mean age was 43.1 ± 15.9 years in the vitamin B12
deficiency group and 40.1 ± 16.9 years in the control
group. In the vitamin B12 deficiency group, 10 (25%) of
the patients were male and 30 (75%) were female; in the
control group, 17 (42.5%) of the participants were male
and 23 (57.5%) were female. There were no differences
between the groups in terms of mean age (P = 0.419) or
sex (P = 0.098) distribution. The demographic data of the
subjects are summarized in Table 1.

The comparisons between serum vitamin B12,
homocysteine, MMA, and urine MMA measurements of
the controls and patients are summarized in Table 2.
Prior to vitamin B12 treatment, there were no
significant differences in TAS (P = 0.694), TOS (P = 0.252),
or OSI (P = 0.189) between the patient and control groups.
The OSI levels of the patients after vitamin B12 treatment
were statistically higher than those of the controls (P
= 0.025). There were no significant differences in TAS
(P = 0.292) or TOS (P = 0.090) between the patient and
control groups. Similar to previous findings, there were
no significant differences between the patients’ pre- and
posttreatment TAS (P = 0.414), TOS (P = 0.505), and OSI
(P = 0.407) measurements (Table 3).
No significant correlations were found between age
and TAS, TOS, and OSI levels before and after treatment,
nor in the changes in posttreatment levels compared to the
pretreatment levels (P > 0.05). Similarly, there were no sexrelated differences in terms of pre- and posttreatment TAS,
TOS, and OSI levels, nor any changes after treatment (P >
0.05).

Table 1. Demographic features of all participants.
Cases (n = 40)

Controls (n = 40)

P

Age, years, mean ± SD

43.1 ± 15.9

40.1 ± 16.9

0.419†

Age range, years, min–max

19–82

19–64

Sex, n (%)

0.098‡

Male

10 (25.0)

17 (42.5)

Female

30 (75.0)

23 (57.5)

† Student’s t-test, ‡ Pearson’s chi-square test.
Table 2. The distribution of serum vitamin B12, homocysteine, methylmalonic acid (MMA) levels, and urine MMA measures of all
subjects.
Pretreatment,
median
(min–max)

Controls,
median
(min–max)

P†

Posttreatment,
median
(min–max)

P‡

P¶

Serum vitamin B12

154 (39–200)

324 (171–1430)

<0.001

706.5 (193–2000)

<0.001

<0.001

Serum homocysteine

13.5 (0–126)

11 (5–21)

<0.021

8 (0–25)

<0.001

<0.001

Serum MMA

1 (0–3)

0 (0–0)

<0.001

0 (0–1)

0.171

<0.001

Urine MMA

2 (0–7)

0 (0–4)

<0.001

0.5 (0–12)

0.702

<0.001

†: Comparison of pretreatment measurements with controls; Mann–Whitney U test.
‡: Comparison of posttreatment levels and controls; Mann–Whitney U test.
¶: Comparison of pre- and posttreatment measurements; Wilcoxon signed rank test.
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Table 3. All subjects’ serum total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI) levels.
Pretreatment,
median
(min–max)

Controls,
median
(min–max)

P†

Posttreatment,
median
(min–max)

P‡

P¶

TOS

3 (0–6)

2 (1–8)

0.252

3 (1–10)

0.090

0.505

TAS

2 (1–2)

2 (1–2)

0.694

2 (1–2)

0.292

0.414

OSI

15 (0–40)

10 (5–80)

0.189

15 (5–50)

0.025

0.407

†: Comparison of pretreatment measurements with controls; Mann–Whitney U test.
‡:Comparison of posttreatment levels and controls; Mann–Whitney U test.
¶: Comparison of pre- and posttreatment measurements; Wilcoxon signed rank test.

4. Discussion
To our knowledge, this is the first study to investigate
serum oxidative metabolism prior to and after vitamin
B12 treatment in adults with vitamin B12 deficiency.
Studies investigating the association of vitamin B12
deficiency or elevated homocysteine levels with oxidative
status have been carried out in patients with different
systemic diseases, such as diabetes mellitus or Parkinson
disease, as well as in vegetarians. In a study conducted
by Herrmann et al., it was found that vegetarians had
a reduced TAS and that vitamin B12 was positively
correlated with TAS. The researchers suggested that
serum vitamin B12, as a marker for functional B12
status, was the variable that influences TAS, and that
functional vitamin B12 deficiency might contribute to
hyperhomocysteinemia and decreased TAS in vegetarians
(12). In another study, low serum levels of glutathione,
TAS, and impaired antioxidant enzymatic activities were
found to be associated with low serum levels of B12 in
adults with type 2 diabetes. It was suggested that low B12
status with low folate was a potential triggering factor for
developing hyperhomocysteinemia and oxidative stress
in adults with type 2 diabetes (8). In a similar study, it
was found that treatment with folate supplementation
lowered levels of plasma homocysteine and serum
malondialdehyde and improved TAS and B12 serum
levels in patients with type 2 diabetes mellitus (13). In
another study, Qureshi et al. suggested that vitamin B12
deficiency was associated with neurotoxicity in Parkinson
disease cases by enhancing oxidative stress (14).
In contrast to other studies, we examined the oxidative
stress parameters in patients with vitamin B12 deficiency
without any other systemic diseases. The TAS, TOS, and
OSI levels of patients with vitamin B12 deficiency in the
pretreatment phase were found to be similar to those of

the controls. There were no significant changes in the
TAS, TOS, and OSI levels of the patients with vitamin
B12 deficiency before and after treatment. Although there
was a significant increase in OSI levels in the patient
group after treatment compared to the controls, we do
not think this finding solely reflects oxidant status, as
there were no significant changes in TAS or TOS levels.
These findings are remarkable in that they show that
cyanocobalamin treatment had no direct effect on the
oxidant and antioxidant statuses of patients with vitamin
B12 deficiency and no other systemic diseases. On the
other hand, the fact that the patients with vitamin B12
deficiency did not differ from the controls in terms of
oxidant and antioxidant status might suggest that oxidative
stress might not play a role in the systemic negative effects
of vitamin B12 deficiency.
The most prominent limitation of this study is the
relatively small sample size. Nevertheless, exclusion of any
comorbid systemic disorders in the vitamin B12 deficiency
sample increased the reliability of our study. In addition,
it is possible that despite the clinical improvement of
hematological symptoms, the clinical symptoms of vitamin
B12 deficiency tend to improve over the longer term;
neurological response to treatment with cyanocobalamin
could take 6 months, for instance, while cellular response
might occur right after vitamin B12 treatment. Therefore,
this study’s design may be another limitation, as the
posttreatment evaluations were conducted only 1 month
after administration. For this reason, there is a need
for further evaluation of oxidative status after a longer
posttreatment period and with a larger sampling.
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